SDZ NKT 343

• Description :

  SDZ NKT 343 is a selective, orally active NK1 receptor antagonist with an IC50 of 0.62 nM against human NK1 receptor. SDZ NKT 343 has good analgesic activity[1][2].

• UNSPSC :

  12352005

• Target :

  Neurokinin Receptor

• Type :

  Reference compound

• Related Pathways :

  GPCR/G Protein; Neuronal Signaling

• Applications :

  Neuroscience-Neuromodulation

• Field of Research :

  Neurological Disease

• Assay Protocol :

  https://www.medchemexpress.com/sdz-nkt-343.html

• Solubility :

  10 mM in DMSO

• Smiles :

  O=C(NC([C@H]1N(C(NC2=CC=CC=C2[N+]([O-])=O)=O)CCC1)=O)[C@H](CC3=CC=C4C=CC=CC4=C3)N(C)CC5=CC=CC=C5

• Molecular Formula :

  C33H33N5O5

• Molecular Weight :

  579.65

• References & Citations :

  [1]Walpole CS, et al. Comparative, general pharmacology of SDZ NKT 343, a novel, selective NK1 receptor antagonist. Br J Pharmacol. 1998 May;124 (1) :83-92. |[2]Walpole C, et al. 2-Nitrophenylcarbamoyl- (S) -prolyl- (S) -3- (2-naphthyl) alanyl-N-benzyl-N - methylamide (SDZ NKT 343), a potent human NK1 tachykinin receptor antagonist with good oral analgesic activity in chronic pain models. J Med Chem. 1998 Aug 13;41 (17) :3159-73.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 1

• Isoform :

  NK1R; NK2R; NK3R

• CAS Number :

  [180046-99-5]